Results of the summarizing process for the arXiv paper: 2304.05153v1

Deep learning (DL) has shown promise in predicting biomarkers from cancer histopathology, but most existing approaches focus on categorical labels rather than continuous measurements. In this study, the researchers aimed to investigate whether regression-based DL outperforms classification-based DL in predicting continuous biomarkers directly from images. To achieve this, they developed a new self-supervised attention-based weakly supervised regression method and evaluated it using a large dataset of 11,671 patients across nine different cancer types. The researchers tested their method on multiple clinically and biologically relevant biomarkers, including the homologous repair deficiency (HRD) score, which is a widely used pan-cancer biomarker. The results showed that using regression significantly improved the accuracy of biomarker prediction compared to classification. Additionally, regression-based scores provided higher prognostic value than classification-based scores in a large cohort of colorectal cancer patients. This suggests that regression-based DL not only enhances the accuracy of biomarker prediction but also improves its interpretability. The study also included an ethics statement confirming that anonymized patient samples from several academic institutions were used with approval from ethical boards. The image data and cohorts consisted of raw whole-slide images (WSIs) scanned by an Aperio ScanSlide scanner and preprocessed for analysis. Two types of clinical targets were analyzed: continuous variables with known clinically relevant cutoffs for categorization and continuous variables without known cutoffs requiring categorization by splitting at the median. The research team described their model pipeline which involved image preprocessing, feature extraction and two approaches for score aggregation: classification based attention attMIL and regression based attMIL. The entire pipeline allowed for patient level predictions based on WSI data. Overall, this study presents a promising alternative for analyzing continuous biomarkers in computational pathology using an open source regression approach. By improving both accuracy and interpretability, regression based DL has the potential to advance biomarker analysis and contribute to personalized cancer care.

• - Deep learning (DL) has shown promise in predicting biomarkers from cancer histopathology
• - Most existing approaches focus on categorical labels rather than continuous measurements
• - Researchers aimed to investigate whether regression-based DL outperforms classification-based DL in predicting continuous biomarkers directly from images
• - Developed a new self-supervised attention-based weakly supervised regression method
• - Evaluated using a large dataset of 11,671 patients across nine different cancer types
• - Tested method on multiple clinically and biologically relevant biomarkers, including the homologous repair deficiency (HRD) score
• - Regression significantly improved accuracy of biomarker prediction compared to classification
• - Regression-based scores provided higher prognostic value than classification-based scores in colorectal cancer patients
• - Regression-based DL enhances accuracy and interpretability of biomarker prediction
• - Anonymized patient samples were used with approval from ethical boards
• - Image data consisted of raw whole-slide images scanned by an Aperio ScanSlide scanner and preprocessed for analysis
• - Two types of clinical targets were analyzed: continuous variables with known cutoffs and continuous variables without known cutoffs requiring categorization by splitting at the median
• - Model pipeline involved image preprocessing, feature extraction, and two approaches for score aggregation: classification based attention attMIL and regression based attMIL.
• - Study presents a promising alternative for analyzing continuous biomarkers in computational pathology using an open source regression approach.

Deep learning (DL) is a type of computer program that can help predict things in cancer pictures. Most programs focus on saying if something is one thing or another, but this program tries to say how much of something there is. The researchers made a new way for the program to learn by itself and pay more attention to important parts of the picture. They tested it on lots of patients with different types of cancer and different things they wanted to know about. The new way worked better than the old way for predicting things in colorectal cancer patients. They used pictures from real patients that were approved by people who make sure things are done ethically." Definitions - Deep learning (DL): A type of computer program that can learn and make predictions. - Biomarkers: Things in the body that can show if someone has a disease or condition. - Histopathology: Looking at cells and tissues under a microscope to see if there are any problems. - Regression: Trying to say how much of something there is, instead of just saying if it's one thing or another. - Classification: Saying if something is one thing or another. - Prognostic value: How helpful something is for predicting what might happen in the future. - Ethical boards: Groups of people who make sure things are done fairly and correctly.

Deep Learning for Predicting Continuous Biomarkers from Cancer Histopathology Images

Cancer is a complex disease that requires accurate and precise biomarker analysis to inform personalized care. Deep learning (DL) has emerged as a powerful tool for predicting biomarkers from cancer histopathology images, but most existing approaches focus on categorical labels rather than continuous measurements. In this study, researchers aimed to investigate whether regression-based DL outperforms classification-based DL in predicting continuous biomarkers directly from images.

Methods

The research team developed a new self-supervised attention-based weakly supervised regression method and evaluated it using a large dataset of 11,671 patients across nine different cancer types. The image data and cohorts consisted of raw whole-slide images (WSIs) scanned by an Aperio ScanSlide scanner and preprocessed for analysis. Two types of clinical targets were analyzed: continuous variables with known clinically relevant cutoffs for categorization and continuous variables without known cutoffs requiring categorization by splitting at the median. The model pipeline included image preprocessing, feature extraction and two approaches for score aggregation: classification based attention attMIL and regression based attMIL. The entire pipeline allowed for patient level predictions based on WSI data.

Results

The results showed that using regression significantly improved the accuracy of biomarker prediction compared to classification when tested on multiple clinically and biologically relevant biomarkers, including the homologous repair deficiency (HRD) score which is a widely used pan-cancer biomarker. Additionally, regression-based scores provided higher prognostic value than classification-based scores in a large cohort of colorectal cancer patients suggesting that not only does it enhance accuracy but also improves interpretability of results obtained through deep learning models applied to medical imaging datasets such as histopathology slides.

Ethics Statement

The study included an ethics statement confirming that anonymized patient samples from several academic institutions were used with approval from ethical boards.

Conclusion

In conclusion, this study presents a promising alternative for analyzing continuous biomarkers in computational pathology using an open source regression approach which can be further extended to other diseases where medical imaging plays an important role in diagnosis or treatment decisions such as cardiovascular diseases or neurological disorders like Alzheimer’s disease or Parkinson’s disease etc.. By improving both accuracy and interpretability, regression based DL has the potential to advance biomarker analysis and contribute to personalized cancer care while also helping clinicians make more informed decisions about their patients' health outcomes